[HTML][HTML] Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community …
AP Abernethy, A Arunachalam, T Burke, C McKay… - PloS one, 2017 - journals.plos.org
Purpose To establish a baseline for care and overall survival (OS) based upon
contemporary first-line treatments prescribed in the era before the introduction of immune …
contemporary first-line treatments prescribed in the era before the introduction of immune …
[HTML][HTML] Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey
H Bailey, A Lee, L Eccles, Y Yuan, H Burlison… - BMC cancer, 2023 - Springer
Background The landscape of non-small cell lung cancer (NSCLC) therapy is rapidly
changing. This analysis aimed to understand patient characteristics, diagnosis and …
changing. This analysis aimed to understand patient characteristics, diagnosis and …
[HTML][HTML] Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these …
SS Shimamura, T Shukuya, T Asao, D Hayakawa… - BMC cancer, 2022 - Springer
Background The prognosis of patients with NSCLC harboring oncogenic driver gene
alterations, such as EGFR gene mutations or ALK fusion, has improved dramatically with the …
alterations, such as EGFR gene mutations or ALK fusion, has improved dramatically with the …
[HTML][HTML] Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
[HTML][HTML] Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with≥ 50% expression of programmed cell …
V Velcheti, X Hu, L Yang, MC Pietanza… - Frontiers in …, 2022 - frontiersin.org
Objectives Immune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed cell
death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line …
death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line …
Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A …
H Liang, X Song, Y Zhang, S Zhang, F Li… - Thoracic …, 2019 - Wiley Online Library
Background Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for
patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth …
patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth …
Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world
A Shokoohi, Z Al‐Hashami, S Moore… - Cancer …, 2022 - Wiley Online Library
The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC)
has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The …
has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The …
Advanced non–small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations
EK Singhi, L Horn, LV Sequist, J Heymach… - American Society of …, 2019 - ascopubs.org
Personalized therapy based on actionable molecular markers has completely transformed
the therapeutic landscape in advanced non–small cell lung cancer (NSCLC). In less than 15 …
the therapeutic landscape in advanced non–small cell lung cancer (NSCLC). In less than 15 …
[HTML][HTML] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
V Velcheti, X Hu, B Piperdi, T Burke - Scientific reports, 2021 - nature.com
Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
[HTML][HTML] Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
NN Lou, XC Zhang, HJ Chen, Q Zhou, LX Yan, Z Xie… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The co-occurrence of epidermal growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) rearrangements constitutes a rare molecular subtype of non-small …
lymphoma kinase (ALK) rearrangements constitutes a rare molecular subtype of non-small …